吃利伐沙班需要注意什么？

Rivaroxaban, as a new oral anticoagulant, can selectively and directly inhibit coagulation factor Xa without the assistance of antithrombin cofactors, inhibiting the generation of thrombin and the formation of thrombus. This is also where it is different from the anticoagulant mechanism of traditional anticoagulants (such as low molecular weight heparin). It has good compliance and is more convenient to use. Moreover, the clinical efficacy and safety of use have been confirmed by clinical trials. In order to ensure that patients can get the maximum benefit from it, patients need to pay close attention to the following points during medication:

1. When using rivaroxaban clinically, the dose needs to be adjusted according to the patient’s renal function to avoid adverse reactions. The results of a study on the effects of rivaroxaban on renal function involving 32 subjects showed that volunteers with mild, moderate and severe renal impairment had 44%, 52% and 64% higher renal damage rates respectively than healthy volunteers. In patients with mild, moderate and severe renal impairment, urinary excretion of unchanged drug dropped to 20%, 13% and 10% respectively, compared with 29% in healthy controls. The clearance rate of rivaroxaban decreases with the increase in the degree of renal damage. The overall inhibition rate of factor Xa activity in patients with mild, moderate and severe renal impairment is 1.5, 1.9 and 2.0 times that of healthy controls, respectively; PT prolongation increases in a similar manner, being 1.3, 2.2 and 2.4 times respectively.

2. Rivaroxaban (i.e. Xarelto) is contraindicated in patients with liver disease who have coagulation abnormalities and clinically relevant bleeding risks. A single oral dose of rivaroxaban 10 was administered to 32 volunteers. mg, the changes in pharmacokinetic and pharmacodynamic parameters in patients with mild or moderate liver damage were observed. The results showed that the pharmacokinetic parameters in patients with mild liver damage only changed slightly, and the AUC increased by an average of 15%, with no significant difference. In patients with moderate liver damage, the pharmacodynamic parameters of rivaroxaban were significantly enhanced, the Xa activity inhibition rate increased by 2.6 times, and the PT was prolonged by 2.1 times. The terminal half-life of patients with mild or moderate liver damage was approximately 2 hours longer than that of healthy volunteers.

  Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: